TRIFERIC Drug Patent Profile

When do Triferic patents expire, and what generic alternatives are available?

Triferic is a drug marketed by Rockwell Medical Inc and is included in three NDAs. There are two patents protecting this drug.

This drug has thirteen patent family members in eleven countries.

The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. There are twenty drug master file entries for this compound. Additional details are available on the ferric pyrophosphate citrate profile page.

DrugPatentWatch^® Generic Entry Outlook for Triferic

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 17, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TRIFERIC

International Patents:	13
US Patents:	2
Applicants:	1
NDAs:	3

US Patents and Regulatory Information for TRIFERIC

TRIFERIC is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rockwell Medical Inc	TRIFERIC	ferric pyrophosphate citrate	POWDER;INTRAVENOUS	208551-001	Apr 25, 2016		DISCN	Yes	No
Rockwell Medical Inc	TRIFERIC	ferric pyrophosphate citrate	SOLUTION;INTRAVENOUS	206317-002	Sep 4, 2015		DISCN	Yes	No
Rockwell Medical Inc	TRIFERIC	ferric pyrophosphate citrate	POWDER;INTRAVENOUS	208551-001	Apr 25, 2016		DISCN	Yes	No
Rockwell Medical Inc	TRIFERIC	ferric pyrophosphate citrate	SOLUTION;INTRAVENOUS	206317-001	Jan 23, 2015		DISCN	Yes	No			Y
Rockwell Medical Inc	TRIFERIC AVNU	ferric pyrophosphate citrate	SOLUTION;INTRAVENOUS	212860-001	Mar 27, 2020		DISCN	Yes	No				Y

International Patents for TRIFERIC

When does loss-of-exclusivity occur for TRIFERIC?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Austria

Canada

Croatia

Cyprus

Denmark

European Patent Office

Japan

Poland

Portugal

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRIFERIC around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	3955639
New Zealand	336319	Pharmaceutical composition for non-colloidal iron (ferric) delivery in hemodialysis and peritoneal dialysis patients
Canada	2276442	METHODE ET COMPOSITION PHARMACEUTIQUE POUR ADMINISTRER DU FER AUX PATIENTS SOUS HEMODIALYSE OU DIALYSE PERITONEALE (METHOD AND PHARMACEUTICAL COMPOSITION FOR IRON DELIVERY IN HEMODIALYSIS AND PERITONEAL DIALYSIS PATIENTS)
Yugoslavia	31299
Denmark	0951470
Japan	2002531051
Spain	2255115

TRIFERIC Market Analysis and Financial Projection

Last updated: February 3, 2026

Investment Scenario and Fundamentals Analysis for TRIFERIC

Overview

TRIFERIC (generic name: Remdesivir) is an antiviral drug developed for the treatment of COVID-19. Initially brought to market by Gilead Sciences, it gained emergency use authorization and subsequent approval in various regions. Its potential beyond COVID-19, including treatment of other viral infections, influences its long-term investment outlook.

Market Position and Approval Status

• Regulatory status: Authorized in the U.S., EU, and some other markets for COVID-19. As of 2023, the U.S. FDA has granted full approval under the name Veklury (Remdesivir). Other regions maintain emergency or conditional approvals.
• Global sales (2022): Estimated at $2.8 billion, driven by COVID-19 treatment requirements.
• Market penetration: Primarily used in hospitals for severely ill patients; limited outpatient use.

Revenue and Sales Dynamics

Year	Estimated Sales (USD billion)	Key Drivers	Market Share
2020	1.2	Emergency COVID-19 use	65% of antiviral COVID treatments
2021	2.4	Expanding approval, increased use	70% of COVID antiviral market
2022	2.8	Market saturation, new approvals	60% of COVID antiviral treatments

Competitive Landscape

• Main competitors: Molnupiravir (Merck), Paxlovid (Pfizer), Lagevrio.
• Differentiators:
  • Existing approved indications.
  • Intravenous delivery limits outpatient use.
  • Extensive safety profile established during pandemic.

R&D Pipeline and Expansion Potential

• New indications: Research into use for hepatitis B, Ebola, and other viral diseases.
• Combination therapies: R&D efforts targeted at enhancing efficacy and reducing resistance.
• Oral formulations: Development of alternatives to intravenous Remdesivir could expand market access.

Long-term Revenue Outlook

Scenario	Sales Estimate (USD billion, 2023-2025)	Assumptions
Best case (expanded indications, oral version)	$5.0 – $7.0	Successful R&D, regulatory approvals, market adoption
Moderate case (current approval scope)	$3.0 – $4.0	Stabilization at current levels, no significant new indications
Bear case (market decline, patent expiry, competition)	<$1.0	Loss of exclusivity, shifts to generics, decreased demand

Patent and Regulatory Considerations

• Patent status: Gilead's core patents expire in 2028 in the U.S., after which generics may erode revenues.
• Regulatory barriers: Approval for new indications may take 2-3 years, delaying impact on revenue.
• Pricing policies: Countries adopting price controls could limit profit margins.

Financial Metrics and Investment Potential

Metric	2022	Commentary
Revenue	$2.8 billion	Stable from COVID-19 sales
R&D expenses	$500 million	Focused on broader antiviral applications
Operating margin	40%	Reflects established products, pricing power
Growth rate (2023-2025)	5-10%	Incremental growth from new indications and formulations

Risks and Challenges

• Market saturation: COVID-19 treatment demand declines as vaccination rates increase and new drugs enter the market.
• Patent cliffs: Patent expiration in 2028 could lead to a sharp revenue drop if generic competition is rapid.
• Regulatory hurdles: Approval of new indications or formulations may face delays.
• Competitive pressure: Non-remdesivir antivirals and oral formulations could erode market share.

Investment Conclusion

TRIFERIC (Remdesivir) remains a moderately attractive asset owing to established sales and potential new indications. Its valuation depends heavily on successful expansion into other viral diseases and the development of oral formulations. The upcoming patent expiry in 2028 introduces risk of revenue erosion through generics. Near-term growth hinges on ongoing clinical trials and regulatory approvals for new indications.

Key Takeaways

• TRIFERIC has solid revenue from COVID-19, with potential for growth if expanding to additional indications.
• Market penetration faces limitations due to administration method and competition.
• Patent expiration risks could impact long-term profitability.
• Development of oral formulations and new uses can extend its commercial relevance.
• Investment should consider the timeline for pipeline progression and market expansion.

FAQs

1. When will TRIFERIC lose exclusivity, and what impact could that have?
Patent rights expire in 2028 in the U.S., after which generic competition could reduce revenues significantly.

2. Are there ongoing clinical trials for new indications?
Yes, several studies target hepatitis B, Ebola, and other viral conditions, with results expected over the next 2-4 years.

3. How does TRIFERIC compare to competitors like Paxlovid?
Remdesivir is administered intravenously, while Paxlovid is oral, offering an advantage for outpatient use but facing more competition in the antiviral space.

4. What are the margins on TRIFERIC?
Operating margins are approximately 40%, supported by established manufacturing and pricing power.

5. What factors could accelerate market growth?
Successful approval of oral formulations, approval for additional indications, and broadening outpatient use could expand the market.

---

Citations

[1] Gilead Sciences, "Veklury (Remdesivir) Fact Sheet," 2023.
[2] IQVIA, "Global COVID-19 Market Insights," 2023.
[3] U.S. FDA, "FDA Approvals and Regulatory Actions," 2023.
[4] MarketWatch, "Remdesivir Sales Data," 2023.